Rosetta Genomics this week announced that it has signed an agreement making Australia's Genetic Technologies the exclusive distributor of its three miRview microRNA-based diagnostics in Australia, New Zealand, and Singapore.
Under the deal, Genetic Technologies will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.
"This is an important first step in Genetic Technologies' move from predictive gene tests into advanced cancer management," Genetic Technologies CEO Paul MacLeman said in a statement.
Financial terms of the arrangement were not disclosed.
Rosetta's arrangement with Genetic Technologies comes a little more than a month after the miRNA shop licensed the Italian rights to the diagnostics to AXA Diagnostics (see RNAi News, 9/10/2009).
In August, Rosetta announced that it has licensed the rights to the diagnostics in India, Saudi Arabia, Qatar, and the United Arab Emirates to India’s Super Religare Laboratories (see RNAi News, 8/20/2009). That same month, Rosetta licensed the diagnostics’ Canadian market rights to Warnex Medical Laboratories (see RNAi News, 8/13/2009).
In April, Rosetta signed a deal giving Prometheus Laboratories the US rights to the three tests (see RNAi News, 4/16/2009). Prometheus has since launched the tests under its ProOnc line (see RNAi News, 10/15/2009).
In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).